Gene: FBN1

2200
ACMICD|ECTOL1|FBN|GPHYSD2|MASS|MFLS|MFS1|OCTD|SGS|SSKS|WMS|WMS2
fibrillin 1
protein-coding
15q21.1
Ensembl:ENSG00000166147 MIM:134797 Vega:OTTHUMG00000172218 UniprotKB:P35555
NG_008805.2
PubMed
0   ANCO-SNPs
ND
5   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.410e-1 (AD)  2.634e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DOPEY10.885
MED140.882
USP480.878
ATR0.876
PEX10.875
CCDC140.875
ALG130.873
TCERG10.873
NAA250.872
MYSM10.871

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FOXJ1-0.376
S100A1-0.362
OR4F5-0.361
EYA2-0.351
PPP1R14B-0.339
WDR38-0.334
CCDC102A-0.333
NKX6-1-0.331
OR4F29-0.33
GHRHR-0.329

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0131862,3-pentanedione"2,3-pentanedione results in increased expression of FBN1 mRNA"25710175
C5779422-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide"2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide results in decreased expression of FBN1 mRNA"26644586
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of FBN1 mRNA"23196670
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of FBN1 mRNA"25380136
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of FBN1 mRNA17562736
D000109AcetylcholineFBN1 protein affects the susceptibility to [Acetylcholine co-treated with Indomethacin]17641673
D020106AcrylamideAcrylamide results in decreased expression of FBN1 mRNA28959563
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of FBN1 mRNA28522335
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FBN1 mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of FBN1 mRNA24449571
C487081belinostatbelinostat results in decreased expression of FBN1 mRNA27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FBN1 mRNA21632981
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FBN1 mRNA15034205|2071347
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FBN1 mRNA27195522
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FBN1 mRNA22300585
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FBN1 mRNA21839799
D004958EstradiolEstradiol results in increased expression of FBN1 mRNA19484750
C006780bisphenol Abisphenol A results in increased methylation of FBN1 promoter27312807
C006780bisphenol Abisphenol A affects the expression of FBN1 mRNA25181051
C005961bis(tri-n-butyltin)oxidebis(tri-n-butyltin)oxide results in increased expression of FBN1 mRNA18958704
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of FBN1 mRNA16239168
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of FBN1 protein14661032
D002330CarmustineCarmustine results in decreased expression of FBN1 mRNA15980968
D002726Chlorogenic AcidChlorogenic Acid results in decreased expression of FBN1 mRNA20706672
D002737ChloropreneChloroprene results in decreased expression of FBN1 mRNA23125180
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of FBN1 mRNA20938992
D003300CopperCopper results in increased expression of FBN1 protein22692975
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of FBN1 mRNA20971185
D003300Copper[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 mRNA22276220
D003300Copper[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 protein22276220
D016572CyclosporineCyclosporine results in increased expression of FBN1 mRNA20106945
D003907DexamethasoneDexamethasone results in decreased expression of FBN1 mRNA25056791
D002945CisplatinCisplatin results in increased expression of FBN1 mRNA21151649
D004041Dietary FatsDietary Fats results in increased expression of FBN1 mRNA18042831
D004041Dietary FatsDietary Fats results in increased expression of FBN1 mRNA21852083
D004041Dietary Fatsresveratrol inhibits the reaction [Dietary Fats results in increased expression of FBN1 mRNA]21852083
C014476diethyl maleatediethyl maleate results in decreased expression of FBN1 mRNA21161181
D004128DimethylnitrosamineDimethylnitrosamine results in increased expression of FBN1 mRNA25380136
D004237DiuronDiuron results in decreased expression of FBN1 mRNA25152437
C118739entinostatentinostat results in decreased expression of FBN1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C045651epigallocatechin gallateepigallocatechin gallate results in decreased expression of FBN1 mRNA20706672
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of FBN1 mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBN1 mRNA22079256
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of FBN1 mRNA17942748
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FBN1 mRNA17942748
C540355fenamidonefenamidone results in increased expression of FBN1 mRNA27029645
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of FBN1 mRNA20938992
C039281furanfuran results in increased expression of FBN1 mRNA27387713
C001277geldanamycingeldanamycin results in increased expression of FBN1 mRNA26705709
D019833GenisteinGenistein results in decreased expression of FBN1 mRNA20706672
C568713GSK1210151AGSK1210151A inhibits the reaction [TGFB1 protein results in increased expression of FBN1 mRNA]26644586
C568713GSK1210151AGSK1210151A results in decreased expression of FBN1 mRNA26644586
C010176halofuginonehalofuginone inhibits the reaction [Thioacetamide results in increased expression of FBN1 protein]17180598
C010176halofuginonehalofuginone results in increased expression of FBN1 mRNA17180598
D017313FenretinideFenretinide results in decreased expression of FBN1 mRNA28973697
D01979615-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid"FBN1 protein affects the susceptibility to 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid"17641673
D006923HymecromoneHymecromone results in decreased expression of FBN1 mRNA23139787
D007213IndomethacinFBN1 protein affects the susceptibility to [Acetylcholine co-treated with Indomethacin]17641673
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FBN1 mRNA25613284
C098607JP8 aviation fuelJP8 aviation fuel results in increased expression of FBN1 protein17337753
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [TGFB1 protein results in increased expression of FBN1 mRNA]26644586
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of FBN1 mRNA26644586
D007854LeadLead results in increased expression of FBN1 mRNA19921347
C008261lead acetatelead acetate results in increased expression of FBN1 mRNA20542052
C045463leflunomideleflunomide results in decreased expression of FBN1 mRNA28988120
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of FBN1 mRNA25613284
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of FBN1 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FBN1 mRNA28001369
D009020MorphineMorphine results in decreased expression of FBN1 mRNA21178816
D009151Mustard GasMustard Gas results in decreased expression of FBN1 mRNA15674843
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of FBN1 mRNA"25554681
D0150581-Naphthylisothiocyanate1-Naphthylisothiocyanate results in increased expression of FBN1 mRNA25380136
D009532NickelNickel results in increased expression of FBN1 mRNA25583101
C029938nickel sulfatenickel sulfate results in decreased expression of FBN1 mRNA22714537
D009534NiclosamideNiclosamide results in increased expression of FBN1 mRNA26452273
D009538NicotineNicotine results in increased expression of FBN1 mRNA17456735
C007350nitrofennitrofen results in decreased expression of FBN1 mRNA27522124
C007350nitrofennitrofen results in decreased expression of FBN1 protein27522124
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of FBN1 mRNA20971185
C558013NSC 689534NSC 689534 results in increased expression of FBN1 mRNA20971185
C024713n-tetradecanen-tetradecane results in decreased expression of FBN1 protein17337753
D010047Ovalbumin[Ovalbumin affects the susceptibility to Particulate Matter] which results in increased expression of FBN1 mRNA19176365
D010047Ovalbumin[Particulate Matter co-treated with Ovalbumin] results in increased expression of FBN1 mRNA19176365
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of FBN1 mRNA25729387
C030110oxaliplatinoxaliplatin results in increased expression of FBN1 mRNA25729387
D017239PaclitaxelPaclitaxel results in increased expression of FBN1 mRNA19682730
D000073878Palm OilPalm Oil results in increased expression of FBN1 mRNA18042831
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of FBN1 mRNA26272509
D052638Particulate Matter[Ovalbumin affects the susceptibility to Particulate Matter] which results in increased expression of FBN1 mRNA19176365
D052638Particulate Matter[Particulate Matter co-treated with Ovalbumin] results in increased expression of FBN1 mRNA19176365
D010656PhenylephrineFBN1 protein affects the reaction [Phenylephrine results in increased secretion of Epoprostenol metabolite]17641673
D010656PhenylephrineFBN1 protein affects the reaction [Phenylephrine results in increased secretion of Thromboxane A2 metabolite]17641673
D010656PhenylephrineFBN1 protein affects the reaction [PTGS1 protein affects the susceptibility to Phenylephrine]17641673
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBN1 mRNA"27188386
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls affects the expression of FBN1 mRNA21334430
C474837pomiferinpomiferin results in decreased expression of FBN1 mRNA20706672
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBN1 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of FBN1 mRNA22079256|2271453
D011192Potassium DichromatePotassium Dichromate results in increased expression of FBN1 mRNA23608068
D017035PravastatinPravastatin results in increased expression of FBN1 mRNA27225895
D011374ProgesteroneProgesterone results in increased expression of FBN117510236
D011372ProgestinsProgestins results in decreased expression of FBN1 mRNA19609016
D011429PropolisPropolis results in decreased expression of FBN1 mRNA20706672
D011441PropylthiouracilPropylthiouracil affects the expression of FBN1 mRNA24780913
D011464EpoprostenolFBN1 protein affects the reaction [Phenylephrine results in increased secretion of Epoprostenol metabolite]17641673
C033607puerarinpuerarin results in decreased expression of FBN1 mRNA20706672
C513428pyrachlostrobinpyrachlostrobin results in increased expression of FBN1 mRNA27029645
C502851quinocetonequinocetone results in increased expression of FBN1 mRNA27046791
C059514resveratrolresveratrol inhibits the reaction [Dietary Fats results in increased expression of FBN1 mRNA]21852083
D012176RetinoidsRetinoids analog results in increased expression of FBN1 protein16055107
C529148rosavinrosavin results in decreased expression of FBN1 mRNA20706672
C507164seletinoid Gseletinoid G results in increased expression of FBN1 protein16055107
D012822Silicon DioxideSilicon Dioxide results in decreased expression of FBN1 mRNA22431001
C017947sodium arsenitesodium arsenite affects the methylation of FBN1 gene28589171
C017947sodium arsenitesodium arsenite results in decreased expression of FBN1 mRNA18812580
C075117squalestatin 1squalestatin 1 affects the expression of FBN1 mRNA27225895
C075117squalestatin 1squalestatin 1 results in decreased expression of FBN1 mRNA27225895
D013739TestosteroneTestosterone results in increased expression of FBN1 mRNA22539767
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of FBN1 mRNA21998131
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FBN1 mRNA21570461|2637764
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FBN1 mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of FBN1 mRNA15034205|1794274
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FBN1 mRNA25613284
C020809tetrathiomolybdate[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 mRNA22276220
C020809tetrathiomolybdate[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 protein22276220
D013849ThimerosalThimerosal results in decreased expression of FBN1 mRNA27188386
D013853Thioacetamidehalofuginone inhibits the reaction [Thioacetamide results in increased expression of FBN1 protein]17180598
D013853ThioacetamideThioacetamide results in increased expression of FBN1 protein17180598
D013928Thromboxane A2FBN1 protein affects the reaction [Phenylephrine results in increased secretion of Thromboxane A2 metabolite]17641673
C009495titanium dioxidetitanium dioxide results in increased expression of FBN1 mRNA27760801
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of FBN1 mRNA28111298
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of FBN1 mRNA25729387
D019772TopotecanTopotecan results in increased expression of FBN1 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of FBN1 mRNA21934132
C032910triadimefontriadimefon results in decreased expression of FBN1 mRNA26705709
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of FBN1 mRNA24935251|2627250
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of FBN1 mRNA19042947
C057693troglitazonetroglitazone results in increased expression of FBN1 mRNA19140230
C057693troglitazonetroglitazone results in increased expression of FBN1 mRNA28973697
C022884undecaneundecane results in increased expression of FBN1 protein17337753
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FBN1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of FBN1 mRNA23179753|2438349
D014640VancomycinVancomycin results in decreased expression of FBN1 mRNA18930951
C025643vinclozolinvinclozolin affects the expression of FBN1 mRNA19015723
C025643vinclozolinvinclozolin results in increased expression of FBN1 mRNA23555832
D014800VitalliumVitallium analog results in decreased expression of FBN1 mRNA23825117
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of FBN1 mRNA26272509|2718838
C088658zoledronic acidzoledronic acid results in increased expression of FBN1 mRNA20977926|2471476

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005178integrin binding-IPI12807887  15062093  17158881  
GO:0005179hormone activity-IEA-  
GO:0005201extracellular matrix structural constituent-IBA21873635  
GO:0005201extracellular matrix structural constituent-IDA3536967  
GO:0005509calcium ion binding-IDA7691719  15062093  
GO:0005515protein binding-IPI12429738  15131124  15165854  15790312  17293099  18339631  
19570982  21402694  22355679  24039232  25034023  26601954  
GO:0008201heparin binding-IDA11461921  
GO:0030023extracellular matrix constituent conferring elasticity-IC8120105  
GO:0042802identical protein binding-IPI18448684  24035709  25034023  
GO:0044877protein-containing complex binding-IPI15062093  
GO ID GO Term Qualifier Evidence PubMed
GO:0001501skeletal system development-IMP8188302  
GO:0001656metanephros development-IEA-  
GO:0007507heart development-IMP15781745  
GO:0009653anatomical structure morphogenesis-IBA21873635  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0030198extracellular matrix organization-TAS-  
GO:0033627cell adhesion mediated by integrin-IDA12807887  17158881  
GO:0035582sequestering of BMP in extracellular matrix-ISS-  
GO:0035583sequestering of TGFbeta in extracellular matrix-ISS-  
GO:0043010camera-type eye development-IEP25406291  
GO:0043687post-translational protein modification-TAS-  
GO:0044267cellular protein metabolic process-TAS-  
GO:0045671negative regulation of osteoclast differentiation-IDA24039232  
GO:0048048embryonic eye morphogenesis-IEP25406291  
GO:0048050post-embryonic eye morphogenesis-IEP25406291  
GO:0071560cellular response to transforming growth factor beta stimulus-IEA-  
GO:1990314cellular response to insulin-like growth factor stimulus-IEA-  
GO:2001205negative regulation of osteoclast development-IDA24039232  
GO ID GO Term Qualifier Evidence PubMed
GO:0001527microfibril-IDA1860873  3536967  7534784  8120105  10424889  12429738  22355679  
GO:0005576extracellular region-HDA27068509  
GO:0005576extracellular region-IDA11461921  
GO:0005576extracellular region-TAS-  
GO:0005604basement membrane-IDA3536967  
GO:0005615extracellular space-HDA20551380  
GO:0005615extracellular space-IDA3536967  
GO:0005788endoplasmic reticulum lumen-TAS-  
GO:0031012extracellular matrix-HDA23658023  
GO:0031012extracellular matrix-IBA21873635  
GO:0031012extracellular matrix-IDA3536967  
GO:0062023collagen-containing extracellular matrix-HDA23979707  27559042  
GO:0062023collagen-containing extracellular matrixcolocalizes_withHDA20551380  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1474228Degradation of the extracellular matrixIEA
R-HSA-1474228Degradation of the extracellular matrixTAS
R-HSA-1474244Extracellular matrix organizationTAS
R-HSA-1474244Extracellular matrix organizationIEA
R-HSA-1566948Elastic fibre formationTAS
R-HSA-1566948Elastic fibre formationIEA
R-HSA-2129379Molecules associated with elastic fibresTAS
R-HSA-2129379Molecules associated with elastic fibresIEA
R-HSA-216083Integrin cell surface interactionsTAS
R-HSA-381426Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)TAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-8957275Post-translational protein phosphorylationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24413999Association study of common variations of FBN1 gene and essential hypertension in Han Chinese population. (2014)Chen JMol Biol Rep
12798348Molecular pathogenesis of subarachnoid haemorrhage. (2003 Sep)Zhang BInt J Biochem Cell Biol
28973303FBN1 mutations largely contribute to sporadic non-syndromic aortic dissection. (2017 Dec 15)Tan LHum Mol Genet
17330281Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. (2007 Mar 15)McNearney TAArthritis Rheum
24837032Increased carotid plaque burden in men with the fibrillin-1 2/3 genotype. (2014 Sep)De Basso RClin Exp Pharmacol Physiol